Furthermore, in EC PDX models, combination treatment with dasatinib and capivasertib showed enhanced effectiveness compared with single-agent treatments (Fig. 8, G and H), suggesting that dual-targeted therapies could offer a promising approach to overcome PTEN loss–driven resistance and improve therapeutic efficacy in cancer treatment. Here, PTEN is linked to cancer.